Mesa Laboratories MLAB Clinical Genomics — Cost Of Revenue Other
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Mesa Laboratories in its filing.
Tagged under the XBRL concept mlab:CostOfRevenueOther.
The official record: Mesa Laboratories’s 10-K, filed June 3, 2026, on SEC EDGAR. View the filing →
Ask your AI about Mesa Laboratories's clinical genomics — cost of revenue other.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Mesa Laboratories's clinical genomics — cost of revenue other?
- Mesa Laboratories (MLAB) reported clinical genomics — cost of revenue other of $4.47M in Q1 2026.
- How has Mesa Laboratories's clinical genomics — cost of revenue other changed year-over-year?
- Mesa Laboratories's clinical genomics — cost of revenue other decreased by 7.4% year-over-year, from $4.83M to $4.47M.
- What is the long-term trend for Mesa Laboratories's clinical genomics — cost of revenue other?
- Over 2 years (2024 to 2026), Mesa Laboratories's clinical genomics — cost of revenue other has grown at a -5.4% compound annual growth rate (CAGR), from $20.13M to $18.02M.
- What does clinical genomics — cost of revenue other mean?
- This captures direct production costs within the Clinical Genomics segment that are not classified as depreciation or amortization. It typically includes raw materials, direct labor, and variable overhead necessary to deliver the segment's products and services.